Inflammatory and bone turnover markers in a cross-sectional and prospective study of acute Charcot osteoarthropathy

2014 ◽  
Vol 32 (2) ◽  
pp. 267-273 ◽  
Author(s):  
N. L. Petrova ◽  
T. K. Dew ◽  
R. L. Musto ◽  
R. A. Sherwood ◽  
M. Bates ◽  
...  
Bone ◽  
2012 ◽  
Vol 50 (5) ◽  
pp. 1141-1147 ◽  
Author(s):  
Richard Eastell ◽  
Patrick Garnero ◽  
Christine Audebert ◽  
David L. Cahall

2008 ◽  
Vol 83 (6) ◽  
pp. 388-392 ◽  
Author(s):  
Silvano Adami ◽  
Davide Gatti ◽  
Ombretta Viapiana ◽  
Carmelo Erio Fiore ◽  
Ranuccio Nuti ◽  
...  

2020 ◽  
Vol 26 (12) ◽  
pp. 1442-1450
Author(s):  
Shrinath Shetty ◽  
Kripa Elizabeth Cherian ◽  
Sahana Shetty ◽  
Nitin Kapoor ◽  
Felix K. Jebasingh ◽  
...  

Objective: This prospective study was carried out to assess trabecular bone score, bone mineral density (BMD), and bone biochemistry in Indian subjects with symptomatic primary hyperparathyroidism (PHPT), and to study the influence of baseline parathyroid hormone (PTH) on recovery of these parameters following curative surgery. Methods: This was a 2-year prospective study conducted at a tertiary care centre in southern India. Baseline assessment included demographic details, mode of presentation, bone mineral biochemistry, BMD, trabecular bone score (TBS), and bone turnover markers (BTMs). These parameters were reassessed at the end of the first and second years following curative parathyroid surgery. Results: Fifty-one subjects (32 men and 19 women) with PHPT who had undergone curative parathyroidectomy were included in this study. The mean (SD) age was 44.6 (13.7) years. The TBS, BTMs, and BMD at lumbar spine and forearm were significantly worse at baseline in subjects with higher baseline PTH (≥250 pg/mL) when compared to the group with lower baseline PTH (<250 pg/mL). At the end of 2 years, the difference between high versus low PTH groups (mean ± SD) persisted only for forearm BMD (0.638 ± 0.093 versus 0.698 ± 0.041 g/cm2; P = .01). However, on follow-up visits in the first and second year after curative parathyroidectomy, there was no significant difference in BTMs, BMD at the femoral neck, lumbar spine, and TBS between the 2 groups stratified by baseline PTH. Conclusion: The BMD at the forearm remained significantly worse in individuals with high baseline PTH even at 2 years after surgery, while other parameters including TBS improved significantly from baseline. Abbreviations: 25(OH)D = 25-hydroxyvitamin D; BMD = bone mineral density; BMI = body mass index; BTMs = Bone turnover markers; CTX = C-terminal telopeptide of type 1 collagen; DXA = dual energy X-ray absorptiometry; P1NP = N-terminal propeptide of type 1 procollagen; PHPT = primary hyperparathyroidism; PTH = parathyroid hormone; TBS = trabecular bone score


Author(s):  
Yosuke Nakagawa ◽  
Hirotaka Komaba ◽  
Naoto Hamano ◽  
Hisae Tanaka ◽  
Takehiko Wada ◽  
...  

Abstract Context Sclerostin is an osteocyte-derived inhibitor of bone formation and is increased in kidney failure, but its role in the pathogenesis of renal bone disease remains unknown. Objective To explore the association of serum sclerostin with bone metabolism in patients undergoing hemodialysis, with a particular focus on parathyroid hormone (PTH)-dependent and PTH-independent pathways. Design Cross-sectional and prospective cohort study. Setting and participants 654 patients undergoing hemodialysis at 10 facilities in Japan. Main outcome measures We employed multivariable linear regression to explore whether sclerostin levels were associated with metacarpal bone mineral density (BMD), intact PTH, bone alkaline phosphatase (BAP), and tartrate-resistant acid phosphatase-5b (TRACP-5b). We employed mediation analyses to explore whether and to what extent the association of PTH with bone turnover markers is mediated by sclerostin. We also compared sclerostin levels between patients with and without previous or incident fractures. Results The median sclerostin level in hemodialysis patients was 3–4-fold higher than that in healthy individuals. Higher sclerostin levels were associated with higher metacarpal BMD and lower levels of intact PTH, BAP, and TRACP-5b. However, the relationships of sclerostin with bone turnover markers were substantially attenuated after adjustment for PTH. Mediation analysis suggested that the effects of PTH on bone turnover markers were mainly direct rather than mediated by sclerostin. Sclerostin levels were not associated with previous or incident fractures. Conclusions These findings suggest that in patients undergoing dialysis, sclerostin has only a limited role in bone metabolism and may not mediate the effect of PTH on bone turnover.


2018 ◽  
Vol 29 (2) ◽  
pp. e137-e140 ◽  
Author(s):  
Andre Peisker ◽  
Gregor F. Raschke ◽  
Mina D. Fahmy ◽  
Arndt Guentsch ◽  
Korosh Roshanghias ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document